Raynovent focuses on development of innovative for the treatment of Influenza, Non-Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF), etc., on the strength of our comprehension and insights of respiratory and liver diseases.
For ZSP1273, the influenza drug candidate which is of great value in commerce and public health emergency, we are simultaneously developing oral solid dosage form, granule formulation, inhalation formulation, etc. for different patients, including adults, children, and critically ill patients.
To fullfill the urgent unmet need in NASH, our pipeline has covered diverse targets in different pathogenesis disease stages, including steatosis, inflammation, fibrosis and is of good potential for combination therapy.